Skip to main content

roche-qiagen-logo

Swiss drugmaker Roche said on Wednesday it had entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents, pertaining to the detection of mutations in the EGFR pathway.

{iframe}http://www.reuters.com/article/2015/01/14/roche-qiagen-idUSFWN0UR05820150114{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.